Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim about boxed-warning hepatotoxicity risk in children under 2 years and the associated extreme caution/sole-agent use and liver function test monitoring (prior to therapy and frequently thereafter, especially in the first 6 months) is directly supported by the supplied FDA label excerpts. No direct contradictions were identified, and the claim does not add information beyond what is present in the excerpts.
Category Scores
Accurate Statements
Children under age 2 years are at a considerably increased risk of developing fatal hepatotoxicity.
BOXED WARNING — HEPATOTOXICITY; 5 WARNINGS — Hepatotoxicity
When divalproex sodium delayed-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent.
BOXED WARNING — HEPATOTOXICITY; 5 WARNINGS — Hepatotoxicity
Incidents usually have occurred during the first six months of treatment.
BOXED WARNING — HEPATOTOXICITY
Patients should be monitored closely and liver function tests should be performed prior to therapy and at frequent intervals thereafter (especially during the first six months).
BOXED WARNING — HEPATOTOXICITY; 5 WARNINGS — Hepatotoxicity
Unsupported Statements
warrants extreme caution/sole-agent use, and requires close monitoring with liver function tests prior to therapy and frequently thereafter (especially during the first 6 months).
This is supported by the label excerpts; therefore not actually unsupported. No unsupported statements were identified in the provided claim.
Contradictions
Important Omissions
The claim does not explicitly include the boxed-warning examples of nonspecific premonitory symptoms (e.g., malaise, weakness, lethargy, facial edema, anorexia, vomiting).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The statements assessed are consistent with the label’s boxed warning and hepatotoxicity monitoring guidance for children under 2 years. No label-inconsistent or potentially unsafe additions were present in the claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor omission: specific nonspecific symptom examples are not included (not required for correctness of the core monitoring statement).
Suggested Improvement
If quoting or expanding, include the label’s listed nonspecific symptoms (malaise, weakness, lethargy, facial edema, anorexia, vomiting) and note monitoring for loss of seizure control in patients with epilepsy, as applicable.